Programme

Click on each session and speaker for further details

Each session aims to address a key problem in the breast cancer research field from both a clinical and research perspective through expert speakers, discussion and debate.

Day 1
15 Jan 2018
Day 2
16 Jan 2018

Exchange Auditorium: Opening address

Professor Mitch Dowsett
Baroness Delyth Morgan

Baroness Delyth Morgan
Baroness Delyth Morgan
Professor Mitch Dowsett
Professor Mitch Dowsett

Exchange Auditorium: Highlights of 2017

09.10
Basic research: Professor Clare Isacke

09.30
Translational research:   Professor Peter Schmid

10.20
Early Disease:  Professor Michael Gnant

10.40
Late Disease:   Dr Mark Verrill

Chairs: Dr Daniel Hayes & Professor Arnie Purushotham

Professor Clare Isacke
Professor Clare Isacke
Professor Peter Schmid
Professor Peter Schmid
Dr. Michael Gnant
Professor Michael Gnant
Dr. Daniel Hayes
Dr Daniel Hayes
Arnie Purushotham
Professor Arnie Purushotham

Exchange Auditorium: Key Note Lecture: Dr Laura Esserman

Innovation in Neoadjuvant Chemotherapy

Chair: Miss Julie Doughty

Dr. Laura Esserman
Dr Laura Esserman

Exchange Auditorium: Metastatic Disease

11.30
Managing ER+ disease:                 
Professor Stephen Johnston

11.50
Predicting outcome in metastatic breast cancer: 
Dr Aleix Prat

12.10
Evolution of resistance:
Professor Adrian Harris

12.30
Selected Free Communication:
RADICL phase lb/lla study of AZD4547 combined with anastrozole or letrozole in AI resistant ER+ breast cancer patients
Professor Michael Seckl, Imperial College London

Chairs: Professor Andrew Tutt & Dr Catherine Harper-Wynne

Professor Stephen Johnston
Professor Stephen Johnston
Dr. Aleix Prat
Dr Aleix Prat
Professor Adrian Harris
Professor Adrian Harris
Professor Andrew Tutt
Professor Andrew Tutt
Dr Catherine Harper-Wynne
Dr Catherine Harper-Wynne

Charter 1: Ductal Carcinoma In Situ

11.30
Avoiding overtreatment of DCIS
Dr Judy Boughey

11.50
How wide a margin do we need for DCIS?
Professor Sarah Pinder

12.10
Should radiotherapy be routinely recommended after wide local excision of DCIS?
Professor David Dodwell

12.30
Selected Free Communication:
Does immediate breast reconstruction delay the delivery of adjuvant treatment: The iBRA-2 prospective multicentre cohort study
The Breast Reconstruction Research Collaborative

Chairs: Dr Anthony Maxwell & Mr Mark Sibbering

Dr Judy Boughey
Professor David Dodwell
Professor David Dodwell
Mark Sibbering
Mr Mark Sibbering
Dr. Tony Maxwell
Dr Anthony Maxwell
Professor Sarah Pinder
Professor Sarah Pinder

Charter 2 & 3: Model systems

11.30
The use of patient-derived tissues for advanced, preclinical models of breast cancer                                                          
Dr Rob Clarke

11.50
Organoid models
Dr Mathew Garnett

12.10
3D in vitro modelling using material from Breast Cancer Now Tissue Bank
Dr Richard Grose

12.30
Selected Free Communication:
Targeting IL1B-Wnt signalling prevents breast cancer colonisation in the bone microenvironment
Dr Rachel Eyre, University of Manchester

Chairs: Professor Ingunn Holen & Professor Valerie Speirs

Dr. Rob Clarke
Dr Rob Clarke
Dr. Mathew Garnett
Dr Mathew Garnett
Dr Richard Grose
Dr Richard Grose
Professor Ingunn Holen
Professor Ingunn Holen
Professor Valerie Speirs
Professor Valerie Speirs

Industry Symposium: Amgen

From past paradigms to future frontiers: Exploring the role of bone modifying agents in breast cancer

12.50 Welcome and introduction
Professor Michael Gnant
12.55 Therapeutic targeting of bone metastasis – from advanced disease to early dissemination
Professor Ingunn Holen
13.10 Bisphosphonates in breast cancer: Past, present and future
Dr Caroline Wilson
13.25 RANK ligand inhibition – past, present and future
Professor Rob Coleman
13.40 Panel discussion & Q&A
Led by Professor Gnant
13.50 Chair’s summary and close
Professor Michael Gnant

Dr. Michael Gnant
Professor Michael Gnant
Professor Ingunn Holen
Professor Ingunn Holen

Industry Symposium: Roche

The role of immunotherapy in breast cancer

12.50
Welcome and Introduction
Dr Judy King
12.55
The application of immuno-oncology to breast cancer – where are we?
Professor Peter Schmid
13.15
What can we learn from the immuno-oncology experience in other tumour types?
Dr Mark Harries
13.35
Questions to the panel
13.45
Summary and close

Professor Peter Schmid
Professor Peter Schmid

Exchange Auditorium: Le Cure Lecture: Dr Marc Lippman

Breast Cancer Research: Past and Future

Chaired by Professor Ian Smith

Dr Marc Lippman
Dr Marc Lippman
Professor Ian Smith
Professor Ian Smith

Exchange Auditorium: Neoadjuvant Therapy

14.35
Neoadjuvant therapy as a surgical tool                                 
Professor Mike Dixon

14.55
Treatment of the axilla post neoadjuvant chemotherapy             
Dr Judy Boughey

15.15
Neera Patel Lecture
RCB vs pCR as an end-point                      
Dr Fraser Symmans

15.35
Imaging end-points for neoadjuvant therapy 
Dr Sarah Vinnicombe

Chairs: Dr Andreas Makris & Professor Ian Smith

Dr. Fraser Symmans
Dr Fraser Symmans
Professor Mike Dixon
Professor Mike Dixon
Dr Judy Boughey
Dr. Sarah Vinniecombe
Dr Sarah Vinnicombe
Dr. Andreas Makris
Dr Andreas Makris
Professor Ian Smith
Professor Ian Smith

Charter 2 & 3: Workshop – A practical guide to shared decision making: Putting research into practice

The benefits of shared decision making
Professor Diana Harcourt
What can help to help make a good decision in a difficult situation like breast cancer?
Dr Alex Clarke
Tools available to support shared decision making about breast reconstruction
Dr Nicole Paraskeva

Chairs: Professor Deborah Fenlon & Mrs Lesley Turner

Mrs Lesley Turner
Professor Diana Harcourt
Professor Diana Harcourt
Dr Alex Clarke
Dr Alex Clarke
Dr Nicole Paraskeva
Dr Nicole Paraskeva
Professor Deborah Fenlon
Professor Deborah Fenlon

Charter 1: Image analysis for scientists and pathologists

14.35
Applying digital pathology to translational breast cancer research
Professor Valerie Speirs
14.55
Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery
Professor Tony Ng
15.15
Deciphering spatial heterogeneity of tumour immune response
Dr Yinyin Yuan

15.35
Selected Free Communication:
Clinicopathological significance of heterogeneity of tumour infiltrating lymphocytes in invasive breast cancer
Miss Maryam Althobiti, University of Nottingham

Chairs: Professor Tony Ng & Professor Sarah Pinder

Professor Tony Ng
Professor Tony Ng
Dr. Yinyin Yuan
Dr Yinyin Yuan
Professor Valerie Speirs
Professor Valerie Speirs
Professor Sarah Pinder
Professor Sarah Pinder

Exchange Auditorium: Selected Free Communications

Chairs: Professor Ian Ellis & Mr Mark Sibbering

16.25 – 16.40
Peri‐operative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer – the POETIC Trial (CRUK/07/015)
Professor Ian Smith, Royal Marsden Hospital, London

16.40 – 16.55
Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces breast cancer recurrence and mortality: an EBCTCG meta-analysis of 34,123 women in 25 randomised trials
Miss Rosie Bradley, University of Oxford

16.55 – 17.10
Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy
Dr Ivana Sestak, Centre for Cancer Prevention, Queen Mary University London

17.10 – 17.25
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn Celecoxib Trial)
Miss Holly Tovey, Institute of Cancer Research, London

17.25 – 17.40
Impact of a BRCA germline mutation on survival – Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH)
Professor Diana Eccles, University of Southampton

Mark Sibbering
Mr Mark Sibbering
Professor Ian Ellis
Professor Ian Ellis

Charter 2 & 3: Costs of treatment

From price to value: Keeping breast cancer care affordable
Professor Richard Sullivan
Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer
Professor Tito Fojo

Chairs: Professor Arnie Purushotham & Mrs Ursula van Mann

Professor Richard Sullivan, Kings College London
Professor Richard Sullivan
Arnie Purushotham
Professor Arnie Purushotham
Ursula Van Mann
Mrs Ursula Van Mann

Charter 1: Triple Negative Breast Cancer

16.25
The biology of new targets
Professor Andrew Tutt

16.45
Precision medicine for triple negative breast cancer patients using a systems biology approach
Dr Chuck Perou

17.05
Immunologic advances
Professor Giuseppe Curigliano

17.25
Selected Free Communication:
Comprehensive molecular characterisation of TNBCs expressing HORMAD1, a driver of homologous recombination deficiency
Mr Jelmar Quist, King’s College London

Chairs: Professor Andrew Tutt and Professor Ingunn Holen

Dr Charles Perou
Professor Ingunn Holen
Professor Ingunn Holen
Professor Andrew Tutt
Professor Andrew Tutt

Exchange Auditorium: Key Note Lecture: Professor Sir David Spiegelhalter

Understanding Risk

Chair: Professor Dame Lesley Fallowfield

Professor Sir David Spiegelhalter
Professor Sir David Spiegelhalter
Professor Dame Lesley Fallowfield
Professor Dame Lesley Fallowfield

Industry Symposium: Daiichi-Sankyo

HER2+ breast cancer: Where are we now, where next?

Industry Symposium: Novartis

MDT live: Clinical case decision making at the front line

07.45-07.50
Welcome and introduction
Dr Mark Verrill
07.50 – 07.55
Introducing CDK pathway inhibition
– A milestone moment for metastatic
breast cancer
Professor Andrew Wardley
07.55 – 08.40
Informed decisions with ribociclib –
decision making and practical advice
for first-line HR+/HER2-locally
advanced or metastatic breast cancer
Dr Mark Verrill (Chair); Professor Andrew
Wardley; Professor Samreen Ahmed; Dr
Vickki Harmer

08.40 – 08.45
Concluding remarks
Dr Mark Verrill

Exchange Auditorium: Key Note Lecture, sponsored by BACR: Professor Jack Cuzick

Breast Cancer Prevention for the Population at Large

Chair: Professor Gareth Evans

Professor Gareth Evans
Professor Jack Cuzick
Professor Jack Cuzick

Exchange Auditorium: Measuring and managing breast cancer risk

09.35
Stratification of Screening                              
Professor Fiona Gilbert

09.55
Risk prediction for risk reduction
Professor Gareth Evans

10.15
Findings from the Generations Study             
Professor Tony Swerdlow

10.35
Identifying genetic risk in the prevalent breast cancer population
Professor Nazneen Rahman

Chairs: Dr Anthony Maxwell & Ms Christine Lee-Jones

Professor Fiona Gilbert
Professor Fiona Gilbert
Tony Swerdlow
Professor Tony Swerdlow
Professor Gareth Evans
Dr. Tony Maxwell
Dr Anthony Maxwell

Charter 1: Novel Clinical Trial End-points

09.35
Why do we need better trial endpoints?
Professor Judith Bliss
09.55
Novel trial endpoints: Opportunities and challenges for new surrogate endpoints
Dr Marc Buyse
10.35
Discussion

Chairs: Professor Judith Bliss & Professor Nick Turner

Judith Bliss
Professor Judith Bliss
Dr. Marc Buyse
Dr Marc Buyse
Dr Nicholas Turner
Professor Nicholas Turner

Charter 2 & 3: Breast cancer heterogeneity and evolution

09.35
Genomic hetererogeneity of breast cancer
Dr Lucy Yates

09.55
Experimental modelling of heterogeneity
Dr Rachael Natrajan

10.15
Relevance to the histopathologist
Dr Fraser Symmans

10.35
Selected Free Communication
Comparative transcriptomic analysis of long-term neoadjuvant letrozole-treated dormant and acquired resistant tumours using sequential clinical samples
Dr Cigdem Selli, Edinburgh

Chairs: Professor Stephen Johnston & Professor Carlos Caldas

Professor Stephen Johnston
Professor Stephen Johnston
Dr. Fraser Symmans
Dr Fraser Symmans
Professor Carlos Caldas
Professor Carlos Caldas
Dr. Lucy Yates
Dr Lucy Yates
Dr. Rachel Natrajan
Dr Rachael Natrajan

Exchange Auditorium: New treatments and measuring their impact

11.25
CDK4/6i       
Professor Nicholas Turner

11.45
New Selective Oestrogen Receptor Downregulators   
Dr Lesley-Ann Martin

12.05
Liquid biopsies
Professor Jacqui Shaw

12.25
Selected Free Communication:
Finding determinants of PARP inhibitor sensitivity using genome-wide and focused CRISPR screens
Dr Stephen Pettitt, Institute of Cancer Research, London

Chairs: Dr Julia Gee & Professor Adrian Harris

Dr Lesley-Ann Martin
Dr Julia Gee
Dr Julia Gee
Professor Jacqui Shaw
Professor Adrian Harris
Professor Adrian Harris
Dr Nicholas Turner
Professor Nicholas Turner

Charter 1: Lobular breast cancer

11.25
Unique biology in invasive lobular breast cancer
Professor Steffi Oesterreich

11.45
Genetic aspects
Professor Elinor Sawyer

12.05
Histologic dilemmas
Professor Ian Ellis

12.25
Should lobular phenotype be considered when deciding treatment?
Professor Michael Kerin

Chairs: Professor David Dodwell & Dr Adrienne Morgan

Dr. Steffi Oesterreich
Professor Steffi Oesterreich
Professor Elinor Sawyer
Professor Elinor Sawyer
Professor Michael Kerin
Professor Michael Kerin
Dr Adrienne Morgan
Dr Adrienne Morgan
Professor David Dodwell
Professor David Dodwell
Professor Ian Ellis
Professor Ian Ellis

Charter 2 & 3 Communicating risk in breast cancer

Including communication of genomic test results, and the potential benefits and harms of treatments

Professor Sir David Spiegelhalter &
Professor Dame Lesley Fallowfield

Professor Sir David Spiegelhalter
Professor Sir David Spiegelhalter
Professor Dame Lesley Fallowfield
Professor Dame Lesley Fallowfield

Industry Symposium: Amgen

The role of biosimilars in the changing cancer care landscape
Chair: Dr Helen McBride, Director of Research, Biosimilars, Thousand Oaks

12:55-13:20
The journey of a biosimilar from bench to bedside
Dr Helen McBride

13:20-13:45
Biosimilars: So what?
Dr Mark Verrill

Industry Symposium: Nanostring

Prosigna in context: Clinical evidence and comparative performance with other multi-parameter tests

12.50
Perspective and experience of clinical implications of breast cancer molecular subtype
Dr Aleix Prat
13.10
Prosigna data and beyond: Comparison of genomic tests
Dr Ivana Sestak
13.30
Prosigna in the UK: OPTIMA trial, and other perspectives
Dr Andreas Makris

Dr. Aleix Prat
Dr Aleix Prat
Dr. Andreas Makris
Dr Andreas Makris

Exchange Auditorium: Cridlan Lecture: Dr Chuck Perou

Completion of the Cancer Genome Atlas

Chair: Dr Gillian Ross

Dr Gillian Ross
Dr Charles Perou

Exchange Auditorium: Biomarkers and prognostic profiling

14.35
Lessons from molecular subtyping
Professor Carlos Caldas

14.55
Clinical utility of molecular profiles
Professor Rob Stein

15.15
Identifying who needs extended adjuvant ET
Dr Daniel Hayes

15.35
Mutation-directed therapy
Professor Fabrice Andre

Chairs: Professor Mitch Dowsett & Dr Fraser Symmans

Professor Mitch Dowsett
Professor Mitch Dowsett
Dr. Fraser Symmans
Dr Fraser Symmans
Professor Carlos Caldas
Professor Carlos Caldas
Professor Rob Stein
Professor Rob Stein
Dr. Daniel Hayes
Dr Daniel Hayes
Professor Fabrice Andre
Professor Fabrice Andre

Charter 1: Challenges of local management

14.35
Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary
Dr Andreas Makris

14.55
When is local surgery indicated in metastatic breast cancer
Miss Nicola Roche

15.15
What is the impact of MRI scanning on breast cancer treatment?
Professor Ulrich Bick

15.35
Current and future indications for partial breast radiotherapy
Dr Charlotte Coles

Chairs: Miss Julie Doughty & Dr Catherine Harper-Wynne

Miss Nicola Roche
Miss Nicola Roche
Professor Ulrich Bick
Professor Ulrich Bick
Dr. Andreas Makris
Dr Andreas Makris
Dr. Charlotte Coles
Dr Charlotte Coles
Dr Catherine Harper-Wynne
Dr Catherine Harper-Wynne

Charter 2 & 3: Clinical Trials Roadshow

Selected Free Communications:
14.35
The LORIS Trial: Randomising patients with low or low intermediate grade Ductal Carcinoma In Situ (DCIS) to surgery or active monitoring
Dr Matthew Wallis, Addenbrooke’s Hospital, Cambridge

14.55
The plasmaMATCH Trial: A multiple parallel cohort, open‐label, multi‐centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
Dr Andrew Wardley, The Christie, Manchester

15.15
Trials in conduct and trials in development

Chair: Professor Daniel Rea

Professor Daniel Rea

Exchange Auditorium: Prize presentations

Forrest Prize, awarded by British Breast Group to best selected oral presentation
Breast Cancer Now prize for best poster presentation: Non-clinical and clinical

Exchange Auditorium: Key Note Lecture: Professor David Cameron

Achievements of breast cancer research in the UK

Chair: Baroness Delyth Morgan

Baroness Delyth Morgan
Baroness Delyth Morgan
Professor David Cameron
Professor David Cameron

Exchange Auditorium: Closing remarks

Professor Mitch Dowsett

Professor Mitch Dowsett
Professor Mitch Dowsett

The UK IBCS has achieved 15 CPD credits in accordance with the CPD Scheme of the Royal College of Radiologists